The first large-scale clinical trial of a cannabis derivative known as cannabidiol shows it was able to cut the frequency of severe epileptic seizures by 39 per cent, researchers said Wednesday.
Cannabidiol, or CBD, is derived from cannabis plants, but does not cause users to get high. The study in the New England Journal of Medicine comes after years of anecdotal evidence of cannabidiol’s effects. It focused on young patients with Dravet syndrome, a rare form of epilepsy.
“We still need more research, but this new trial provides more evidence than we have ever had of cannabidiol’s effectiveness as a medication for treatment-resistant epilepsy.”
Researchers used an experimental liquid form of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals. It has not been approved for use by the US Food and Drug Administration.
A total of 120 children and adolescents, aged two to 18, with Dravet Syndrome were randomised to receive either a placebo or CBD, in addition to their usual treatment.
The trial took place at 23 sites in the United States and Europe over the course of 14 weeks.
“Seizure frequency dropped in the CBD-treated group by 39 per cent from a median of nearly 12 convulsive seizures per month before the study to about six,” said the study.
“Three patients’ seizures stopped entirely.”
The placebo group saw a much smaller 13 per cent reduction in seizures. Most patients reported side effects, most commonly vomiting, fatigue and fever.
A total of 93.4 per cent of patients in the CBD group and 74.6 per cent of those treated with placebo experienced side effects, which were generally reported as mild or moderate.
But eight patients in the CBD group withdrew from the trial because of side effects, compared to one participant in the placebo group.